Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EOC317 in Advanced Solid Tumors
NCT03583125Phase 1Unknown
- Sponsor
- EOC Pharma
- Start
- May 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eoc317 in solid tumor, urothelial carcinoma (UC), cholangiocarcinoma (CCA) and 1 more, sponsored by EOC Pharma. Primary endpoint: Dose Limiting Toxicity at 12 months. Status: unknown.
02
Drugs
eoc317
03
Conditions
solid tumorurothelial carcinoma (UC)cholangiocarcinoma (CCA)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03583125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03583125.